Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028
The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.
“The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market”
Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.
“infectious disease segment accounted for the largest share of the disease type segment in 2022.”
Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.
“Asia Pacific region is likely to grow at a faster pace.”
The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 80%, and Demand Side - 20%
By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
List of Companies Profiled in the Report:
Dynavax Technologies (US)
Croda International plc (UK)
GSK plc (UK)
Seppic (France)
Novavax (US)
SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
Agenus Inc. (US)
Phibro Animal Health Corporation (US)
Aurorium (Vertellus) (US)
Merck KGaA (Germany)
Vaxine Pty Ltd. (Australia)
Hawaii Biotech Inc. (US)
CSL Limited (Australia)
OZ Biosciences (US)
InvivoGen (US)
Allergy Therapeutics (UK)
EuBiologics Co., Ltd. (South Korea)
Pacific GeneTech Limited (US)
Riboxx GmbH (Germany)
CaPtivate Pharmaceuticals LLC (US)
Creative Diagnostics (US)
LiteVax BV (Netherlands)
Mukta Industries (India)
Oncovir, Inc. (US)
TiterMax USA, Inc. (US).
Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.
Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.
Market Development: Comprehensive information about lucrative markets – the report analyses the vaccine adjuvants market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.